Bristol-Myers Squibb has won a $752 million lawsuit against Gilead Sciences to settle a U.S. patent dispute regarding the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.
A Los Angeles jury found that axicabtagene ciloleucel, a treatment for large B-cell lymphoma sold by Gilead’s Kite Pharma division, infringed on a patent exclusively licensed from the Memorial Sloan Kettering Cancer Center by Bristol-Myers’ Juno Therapeutics.
Gilead plans to appeal the verdict. “We remain steadfast in our opinion that Sloan Kettering’s patent is not infringed and is invalid,” the company said in a statement. “Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages.”